Physician profile
David J Riddle
NPI 1215102660
$5,989.73
in general payments reported to CMS, 2019-2025
40 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $1,016 · 2021: $1,201 · 2022: $1,311 · 2023: $585 · 2024: $368 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $687.76 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $585.71 | 2021-2025 | |
| Pfizer INC. | $573.64 | 2019-2025 | |
| Gilead Sciences, INC. | $514.54 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $381.66 | 2019-2021 | |
| Amgen INC. | $326.70 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Lilly USA, LLC | $325.51 | 2019-2024 | Zepbound, Trulicity, Mounjaro |
| Viiv Healthcare Company | $321.12 | 2019-2022 | |
| Astellas Pharma US INC | $272.88 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.28 | 2019-2022 | |
| Eisai INC. | $169.23 | 2020-2022 | |
| Abbott Laboratories | $154.34 | 2022-2023 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $136.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $134.47 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $125.05 | 2023-2025 | Dexcom G6 Transmitter |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.